INVO Bioscience merger partner NAYA Biosciences signs research partnership

NAYA Biosciences, which has recently signed a definitive merger agreement with INVO Bioscience to establish an expanded, publicly-traded life science company dedicated to increasing patient access to breakthrough treatments in fertility, oncology, and regenerative medicine, and ONK Therapeutics, a cell therapy company dedicated to developing the next generation of optimally engineered off-the-shelf natural killer – NK – cell therapies, have entered into a research partnership to evaluate combination therapy consisting of NAYA’s FLEX-NK bispecific antibodies and ONK’s optimally engineered NK cells. The merger has been unanimously approved by the board of directors of each company and is expected to close in Q1 2024. NAYA and ONK plan to assess several combination therapies in preclinical cancer models in 2024 prior to subsequently exploring initiating clinical trials. Both companies will share the costs of manufacturing and preclinical assessments.